German industry concern over DEHP motive:
This article was originally published in Clinica
Executive Summary
The German health ministry's federal pharmaceutical and medical technology research institute's (BfArM) resurrection last month of the debate on DEHP and its current uses in medical devices has been viewed with suspicion by local industry association Spectaris. International environmental groups urge caution in the use of the PVC softener in neonates and pre-pubescent males, among other recommendations. BfArM has put up for debate a proposal that the replacement of DEHP-containing products with alternatives be the subject of a legal order in Germany (see Clinica No 1143, p 6). Spectaris said in its January infoletter that the industry would reject any such move that would, in fact, see Germany taking a lone stance in this respect.
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.